Search Results

August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics Inc (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed In addition, Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal This week’s issue focuses on structure, early safety strategy, and the next wave of signal transduction GPCR University has undergone a structural redesign. Align your team around structured learning outcomes, not scattered slide decks. It is structured access and structured education.

Structured continuity.   explores the open-access 7TMR-Raft database cataloguing GPCR–lipid raft associations and the expanding therapeutic It is structured access to a field. It supports scientists refining expertise. Structured access creates momentum. Premium delivers that — consistently. Join Dr. GPCR Premium — Build Your Structured Advantage ➤

Joseph Kim exploring GPCR structural biology, cryo-electron microscopy, opioid receptor pharmacology, Joseph Kim is a structural biologist studying membrane proteins and GPCR pharmacology. molecular structures inform the design and development of new therapeutics. GPCR Drug Discovery Is Increasingly Structural Modern GPCR drug discovery increasingly integrates structural You could easily imagine separate therapeutic programs targeting those different physiological effects

optimize the design and engineering of more efficacious therapeutics. perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic